temozolomide has been researched along with Glioblastoma with Sarcomatous Component in 31 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma." | 9.15 | Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. ( Butowski, N; Chang, SM; Clarke, J; Costa, BM; Costello, JF; Hristova-Kazmierski, M; Hsieh, E; Lamborn, KR; Nicol, SJ; Nicole, A; Parvataneni, R; Pieper, R; Polley, MY; Prados, MD; Reis, RM; Sneed, PK; Thornton, DE; Vandenberg, S, 2011) |
| "This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma." | 9.14 | Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. ( Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S, 2009) |
| "A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 9.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
| "Gliosarcoma is an uncommon glioblastoma subtype, for which MGMT promoter methylation's relationship with response to temozolomide chemotherapy is unclear." | 8.12 | Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. ( Iorgulescu, JB; Kavouridis, VK; Ligon, KL; Wen, PY, 2022) |
| "Following captopril treatment, MMP-2 protein expression and migratory capabilities of 9 L gliosarcoma cells were assessed in vitro via western blots and scratch wound assays, respectively." | 8.02 | Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model. ( Brem, H; Casaos, J; Huq, S; Mangraviti, A; Paldor, I; Perdomo-Pantoja, A; Pinheiro, L; Tyler, B; Vigilar, V; Wang, Y; Witham, TF, 2021) |
| "Clinical guidelines for gliosarcoma (GSM) are poorly defined and GSM patients are usually treated in accordance with existing guidelines for glioblastoma (GBM), with maximal surgical resection followed by chemoradiation with temozolomide (TMZ)." | 7.83 | Radiotherapy plus concomitant temozolomide in primary gliosarcoma. ( Adeberg, S; Bernhardt, D; Debus, J; Diehl, C; Harrabi, SB; Koelsche, C; Rieken, S; Unterberg, A; von Deimling, A, 2016) |
| "Human GBM-derived cell lines U87, G44, G112, and the gliosarcoma-derived line G28 were treated with EPO, with and without combinations of irradiation or temozolomide (TMZ)." | 7.74 | Erythropoietin augments survival of glioma cells after radiation and temozolomide. ( Ehrenreich, H; Giese, A; Hasselblatt, M; Hassouna, I; Jelkmann, W; Kim, E; Rave-Fränk, M; Schulz-Schaeffer, W; Sperling, S, 2008) |
| "Gliosarcoma was more common in males (n = 31, 67." | 5.39 | Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. ( Brown, PD; Gilbert, MR; McAleer, MF; Prabhu, SS; Walker, GV, 2013) |
| "Primary malignant brain tumors (BT) are the most common and aggressive malignant brain tumor." | 5.38 | Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model. ( Bow, H; Brem, H; Cima, MJ; Langer, R; Masi, BC; Tyler, BM; Wicks, RT; Xue, Y, 2012) |
| "This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma." | 5.15 | Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. ( Butowski, N; Chang, SM; Clarke, J; Costa, BM; Costello, JF; Hristova-Kazmierski, M; Hsieh, E; Lamborn, KR; Nicol, SJ; Nicole, A; Parvataneni, R; Pieper, R; Polley, MY; Prados, MD; Reis, RM; Sneed, PK; Thornton, DE; Vandenberg, S, 2011) |
| "This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma." | 5.14 | Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. ( Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S, 2009) |
| "A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 5.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
| "Gliosarcoma is an uncommon glioblastoma subtype, for which MGMT promoter methylation's relationship with response to temozolomide chemotherapy is unclear." | 4.12 | Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. ( Iorgulescu, JB; Kavouridis, VK; Ligon, KL; Wen, PY, 2022) |
| "Following captopril treatment, MMP-2 protein expression and migratory capabilities of 9 L gliosarcoma cells were assessed in vitro via western blots and scratch wound assays, respectively." | 4.02 | Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model. ( Brem, H; Casaos, J; Huq, S; Mangraviti, A; Paldor, I; Perdomo-Pantoja, A; Pinheiro, L; Tyler, B; Vigilar, V; Wang, Y; Witham, TF, 2021) |
| " This prospective study included 52 consecutive newly diagnosed glioblastoma (n = 49) or gliosarcoma (n = 3) patients treated with concomitant temozolomide and radiotherapy (RT-TMZ), followed by a TMZ maintenance phase." | 3.96 | Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma. ( Alexandru, C; Beaussire, L; Clatot, F; Di Fiore, F; Fontanilles, M; Hanzen, C; Jardin, F; Langlois, O; Laquerrière, A; Magne, N; Marguet, F; Pépin, LF; Sarafan-Vasseur, N; Tennevet, I, 2020) |
| "Clinical guidelines for gliosarcoma (GSM) are poorly defined and GSM patients are usually treated in accordance with existing guidelines for glioblastoma (GBM), with maximal surgical resection followed by chemoradiation with temozolomide (TMZ)." | 3.83 | Radiotherapy plus concomitant temozolomide in primary gliosarcoma. ( Adeberg, S; Bernhardt, D; Debus, J; Diehl, C; Harrabi, SB; Koelsche, C; Rieken, S; Unterberg, A; von Deimling, A, 2016) |
| "Human GBM-derived cell lines U87, G44, G112, and the gliosarcoma-derived line G28 were treated with EPO, with and without combinations of irradiation or temozolomide (TMZ)." | 3.74 | Erythropoietin augments survival of glioma cells after radiation and temozolomide. ( Ehrenreich, H; Giese, A; Hasselblatt, M; Hassouna, I; Jelkmann, W; Kim, E; Rave-Fränk, M; Schulz-Schaeffer, W; Sperling, S, 2008) |
| "To develop a valid treatment strategy for recurrent high-grade gliomas using stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide." | 3.73 | Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. ( Franz, M; Grosu, AL; Gumprecht, H; Molls, M; Nieder, C; Piert, M; Schwaiger, M; Stärk, S; Thamm, R; Weber, WA, 2005) |
| "Gliosarcoma is a histopathological variant of glioblastoma, which is characterized by a biphasic growth pattern consisting of glial and sarcoma components." | 1.91 | Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study. ( Shen, J; Song, K; Wei, L; Xu, H; Xu, M; Yu, Z; Zhou, Z; Zhu, W, 2023) |
| "The analysis included all patients treated for gliosarcoma between 1998 and 2014 in seven French academic centres." | 1.43 | Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. ( Antoni, D; Berger, A; Biau, J; Castelli, J; Crehange, G; de Crevoisier, R; Feuvret, L; Gutierrez, FL; Haoming, QC; Jouglar, E; Le Reste, PJ; Loussouarn, D; Morandi, X; Noel, G; Nouhaud, E; Thillays, F; Truc, G; Vauleon, E, 2016) |
| " More generally, these results suggest that traditional therapy in combination with local, as opposed to systemic, delivery of angiogenesis inhibitors may be able to increase median survival for patients with glioblastoma." | 1.40 | Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma. ( Bow, H; Brem, H; Hwang, LS; Murray, L; Salditch, Q; Schildhaus, N; Tyler, B; Weingart, J; Xing, J; Ye, X; Zhang, Y, 2014) |
| "Gliosarcoma was more common in males (n = 31, 67." | 1.39 | Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. ( Brown, PD; Gilbert, MR; McAleer, MF; Prabhu, SS; Walker, GV, 2013) |
| "Primary malignant brain tumors (BT) are the most common and aggressive malignant brain tumor." | 1.38 | Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model. ( Bow, H; Brem, H; Cima, MJ; Langer, R; Masi, BC; Tyler, BM; Wicks, RT; Xue, Y, 2012) |
| "Oral temozolomide (TMZ) was administered in combination with mFc-endostatin to determine if there was a beneficial synergistic effect." | 1.37 | Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. ( Brem, H; Grossman, R; Hwang, L; Javaherian, K; Lal, B; Tyler, B; Zadnik, P, 2011) |
| "6% and 1/6 rat survived more than 1 year in case of MRT combined with gadolinium injection." | 1.35 | Enhancement of survival of 9L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy. ( Bräuer-Krisch, E; Bravin, A; Keyriläinen, J; Le Duc, G; Régnard, P; Troprès, I, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (22.58) | 29.6817 |
| 2010's | 16 (51.61) | 24.3611 |
| 2020's | 8 (25.81) | 2.80 |
| Authors | Studies |
|---|---|
| Kavouridis, VK | 1 |
| Ligon, KL | 1 |
| Wen, PY | 1 |
| Iorgulescu, JB | 1 |
| Yu, Z | 1 |
| Zhou, Z | 1 |
| Xu, M | 1 |
| Song, K | 1 |
| Shen, J | 1 |
| Zhu, W | 1 |
| Wei, L | 1 |
| Xu, H | 1 |
| Zhang, Y | 2 |
| Ma, JP | 1 |
| Weng, JC | 1 |
| Wang, L | 1 |
| Wu, Z | 1 |
| Li, D | 1 |
| Zhang, JT | 1 |
| Hsu, BH | 1 |
| Lee, WH | 1 |
| Yang, ST | 1 |
| Han, CT | 1 |
| Tseng, YY | 1 |
| Fontanilles, M | 1 |
| Marguet, F | 1 |
| Beaussire, L | 1 |
| Magne, N | 1 |
| Pépin, LF | 1 |
| Alexandru, C | 1 |
| Tennevet, I | 1 |
| Hanzen, C | 1 |
| Langlois, O | 1 |
| Jardin, F | 1 |
| Laquerrière, A | 1 |
| Sarafan-Vasseur, N | 1 |
| Di Fiore, F | 1 |
| Clatot, F | 1 |
| Wang, X | 1 |
| Jiang, J | 1 |
| Liu, M | 1 |
| You, C | 1 |
| Kiang, KM | 1 |
| Chan, AA | 1 |
| Leung, GK | 1 |
| Pinheiro, L | 1 |
| Perdomo-Pantoja, A | 1 |
| Casaos, J | 1 |
| Huq, S | 1 |
| Paldor, I | 1 |
| Vigilar, V | 1 |
| Mangraviti, A | 1 |
| Wang, Y | 1 |
| Witham, TF | 1 |
| Brem, H | 5 |
| Tyler, B | 3 |
| Bow, H | 2 |
| Hwang, LS | 1 |
| Schildhaus, N | 1 |
| Xing, J | 1 |
| Murray, L | 1 |
| Salditch, Q | 1 |
| Ye, X | 1 |
| Weingart, J | 1 |
| McAleer, MF | 2 |
| Brown, PD | 2 |
| Mallick, S | 1 |
| Gandhi, AK | 1 |
| Sharma, DN | 1 |
| Gupta, S | 1 |
| Haresh, KP | 1 |
| Rath, GK | 1 |
| Julka, PK | 1 |
| Adeberg, S | 1 |
| Bernhardt, D | 1 |
| Harrabi, SB | 1 |
| Diehl, C | 1 |
| Koelsche, C | 1 |
| Rieken, S | 1 |
| Unterberg, A | 1 |
| von Deimling, A | 1 |
| Debus, J | 1 |
| Castelli, J | 1 |
| Feuvret, L | 1 |
| Haoming, QC | 1 |
| Biau, J | 1 |
| Jouglar, E | 1 |
| Berger, A | 1 |
| Truc, G | 1 |
| Gutierrez, FL | 1 |
| Morandi, X | 1 |
| Le Reste, PJ | 1 |
| Thillays, F | 1 |
| Loussouarn, D | 1 |
| Nouhaud, E | 1 |
| Crehange, G | 1 |
| Antoni, D | 1 |
| Vauleon, E | 1 |
| de Crevoisier, R | 1 |
| Noel, G | 1 |
| Régnard, P | 1 |
| Bräuer-Krisch, E | 1 |
| Troprès, I | 1 |
| Keyriläinen, J | 1 |
| Bravin, A | 1 |
| Le Duc, G | 1 |
| Sugiyama, S | 1 |
| Yamashita, Y | 1 |
| Kikuchi, T | 1 |
| Sonoda, Y | 1 |
| Kumabe, T | 1 |
| Tominaga, T | 1 |
| Hassouna, I | 1 |
| Sperling, S | 1 |
| Kim, E | 1 |
| Schulz-Schaeffer, W | 1 |
| Rave-Fränk, M | 1 |
| Hasselblatt, M | 1 |
| Jelkmann, W | 1 |
| Giese, A | 1 |
| Ehrenreich, H | 1 |
| Prados, MD | 4 |
| Chang, SM | 3 |
| Butowski, N | 2 |
| DeBoer, R | 1 |
| Parvataneni, R | 2 |
| Carliner, H | 1 |
| Kabuubi, P | 1 |
| Ayers-Ringler, J | 1 |
| Rabbitt, J | 1 |
| Page, M | 1 |
| Fedoroff, A | 1 |
| Sneed, PK | 2 |
| Berger, MS | 3 |
| McDermott, MW | 3 |
| Parsa, AT | 3 |
| Vandenberg, S | 2 |
| James, CD | 1 |
| Lamborn, KR | 2 |
| Stokoe, D | 1 |
| Haas-Kogan, DA | 1 |
| Oshiro, S | 1 |
| Tsugu, H | 1 |
| Komatsu, F | 1 |
| Ohmura, T | 1 |
| Ohta, M | 1 |
| Sakamoto, S | 1 |
| Fukushima, T | 1 |
| Inoue, T | 1 |
| Han, SJ | 2 |
| Yang, I | 2 |
| Otero, JJ | 2 |
| Ahn, BJ | 2 |
| Tihan, T | 2 |
| Walbert, T | 1 |
| Gilbert, MR | 2 |
| Groves, MD | 1 |
| Puduvalli, VK | 1 |
| Yung, WK | 2 |
| Conrad, CA | 1 |
| Bobustuc, GC | 1 |
| Colman, H | 1 |
| Hsu, SH | 1 |
| Bekele, BN | 1 |
| Qiao, W | 1 |
| Levin, VA | 2 |
| Scott, AW | 1 |
| Tyler, BM | 2 |
| Masi, BC | 2 |
| Upadhyay, UM | 1 |
| Patta, YR | 1 |
| Grossman, R | 2 |
| Basaldella, L | 1 |
| Langer, RS | 1 |
| Cima, MJ | 2 |
| Cohen, KJ | 1 |
| Pollack, IF | 1 |
| Zhou, T | 1 |
| Buxton, A | 1 |
| Holmes, EJ | 1 |
| Burger, PC | 1 |
| Brat, DJ | 1 |
| Rosenblum, MK | 1 |
| Hamilton, RL | 1 |
| Lavey, RS | 1 |
| Heideman, RL | 1 |
| Biswas, A | 1 |
| Kumar, N | 1 |
| Kumar, P | 1 |
| Vasishta, RK | 1 |
| Gupta, K | 1 |
| Sharma, SC | 1 |
| Patel, F | 1 |
| Mathuriya, SN | 1 |
| Polley, MY | 1 |
| Pieper, R | 1 |
| Costello, JF | 1 |
| Nicole, A | 1 |
| Clarke, J | 1 |
| Hsieh, E | 1 |
| Costa, BM | 1 |
| Reis, RM | 1 |
| Hristova-Kazmierski, M | 1 |
| Nicol, SJ | 1 |
| Thornton, DE | 1 |
| Hwang, L | 1 |
| Zadnik, P | 1 |
| Lal, B | 1 |
| Javaherian, K | 1 |
| Wicks, RT | 1 |
| Xue, Y | 1 |
| Langer, R | 1 |
| Vajtai, I | 1 |
| Vassella, E | 1 |
| Hewer, E | 1 |
| Kappeler, A | 1 |
| Reinert, MM | 1 |
| Walker, GV | 1 |
| Prabhu, SS | 1 |
| Grosu, AL | 1 |
| Weber, WA | 1 |
| Franz, M | 1 |
| Stärk, S | 1 |
| Piert, M | 1 |
| Thamm, R | 1 |
| Gumprecht, H | 1 |
| Schwaiger, M | 1 |
| Molls, M | 1 |
| Nieder, C | 1 |
| Albright, RE | 1 |
| Olson, J | 1 |
| Fredericks, R | 1 |
| Fink, K | 1 |
| Brada, M | 1 |
| Spence, A | 1 |
| Hohl, RJ | 1 |
| Shapiro, W | 1 |
| Glantz, M | 1 |
| Greenberg, H | 1 |
| Selker, RG | 1 |
| Vick, NA | 1 |
| Rampling, R | 1 |
| Friedman, H | 1 |
| Phillips, P | 1 |
| Bruner, J | 1 |
| Yue, N | 1 |
| Osoba, D | 1 |
| Zaknoen, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of the Platelet Level During Radiotherapy Associated With Temozolomide in Patients Treated for Glioblastoma[NCT02617745] | Phase 2 | 244 participants (Actual) | Interventional | 2015-11-30 | Active, not recruiting | ||
| Phase II Study of Tarceva Plus Temodar During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma[NCT00187486] | Phase 2 | 66 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma[NCT00028795] | Phase 2 | 170 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme - a Randomised Phase II Trial[NCT01252459] | Phase 2 | 200 participants (Anticipated) | Interventional | 2011-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients were monitored until death (NCT00187486)
Timeframe: assessment of survival was every 2 months, up to 181 weeks
| Intervention | months (Median) |
|---|---|
| Temodar Plus Tarceva Plus Radiotherapy | 19 |
Progression based on MR imaging using the Modified McDonnald Criteria defined as 25% increase in sum of products of all measured lesions or any new lesion (NCT00187486)
Timeframe: every 2 months measure by MR imaging, up to 39 months
| Intervention | months (Median) |
|---|---|
| Temodar Plus Tarceva Plus Radiotherapy | 8.2 |
2 reviews available for temozolomide and Glioblastoma with Sarcomatous Component
| Article | Year |
|---|---|
Treatments of gliosarcoma of the brain: a systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2021 |
Therapeutic management of gliosarcoma in the temozolomide era.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Management; Gliosarcoma; Hu | 2015 |
4 trials available for temozolomide and Glioblastoma with Sarcomatous Component
| Article | Year |
|---|---|
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2009 |
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child | 2011 |
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2011 |
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
25 other studies available for temozolomide and Glioblastoma with Sarcomatous Component
| Article | Year |
|---|---|
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2022 |
Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study.
Topics: Brain Neoplasms; Glioblastoma; Gliosarcoma; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Progn | 2023 |
The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gliosarcoma; H | 2021 |
Spinal metastasis of glioblastoma multiforme before gliosarcomatous transformation: a case report.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Craniotomy; Fatal Outcome; Female; Gliobl | 2020 |
Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy | 2020 |
Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
Topics: Animals; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Cycle Proteins; Chemoradiotherapy; Cranioto | 2021 |
Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasm | 2021 |
Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Brain Neo | 2014 |
Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Da | 2015 |
Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2016 |
Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2016 |
Enhancement of survival of 9L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvan | 2008 |
Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Combined | 2008 |
Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell M | 2008 |
Efficacy of temozolomide treatment in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother | 2009 |
Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2010 |
Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2010 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxi | 2011 |
Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model.
Topics: Animals; Brain; Brain Neoplasms; Capsules; Dacarbazine; Disease Models, Animal; Drug Delivery System | 2011 |
Primary gliosarcoma--clinical experience from a regional cancer centre in north India.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Care Facilities; Combined Modality | 2011 |
Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineopl | 2011 |
Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Delivery Systems; Equ | 2012 |
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, | 2012 |
Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2013 |
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Topics: Adult; Aged; alpha-Methyltyrosine; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocyt | 2005 |